WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe hidradenitis suppurativa (HS).
The trials, STOP-HS1 and STOP-HS2, achieved their primary endpoint at both tested dosages (45 mg and 75 mg). Patients receiving povorcitinib demonstrated significant improvement in symptoms compared to placebo, with more achieving a 50% reduction in abscess and inflammatory nodule counts by Week 12. Additional data indicated promising outcomes in pain reduction and rapid treatment response.
Safety results were consistent with earlier studies, with povorcitinib showing a well-tolerated profile and no new safety concerns. The trials also revealed enhanced efficacy for patients previously treated with biologic therapies, bolstering its potential as a new option for those with limited success in existing treatments.
With this strong clinical data, Incyte plans to submit regulatory applications globally for povorcitinib as a treatment for hidradenitis suppurativa. The company also intends to share detailed findings at upcoming scientific conferences.
The STOP-HS program included two pivotal trials involving approximately 600 adult patients each, focusing on efficacy, safety, and patient-reported improvements over 12 weeks, followed by a long-term extension period. This development underscores povorcitinib’s potential to address an urgent need for effective, convenient, and well-tolerated treatments in the HS community.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.